Covestor Ltd Has $110,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Covestor Ltd lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 105.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 732 shares of the biopharmaceutical company’s stock after purchasing an additional 375 shares during the period. Covestor Ltd’s holdings in Alnylam Pharmaceuticals were worth $110,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC increased its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Quent Capital LLC increased its holdings in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 12,513 shares during the last quarter. GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. Finally, V Square Quantitative Management LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of a number of recent research reports. Wells Fargo & Company raised their price objective on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the company an “equal weight” rating in a research note on Tuesday, June 25th. Cantor Fitzgerald raised their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. Bank of America raised their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Finally, SVB Leerink raised their price objective on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research note on Tuesday, June 25th. Eight investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $256.73.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the transaction, the director now owns 136 shares in the company, valued at $30,013.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,450 shares of company stock worth $15,287,984. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:ALNY traded down $0.46 during midday trading on Tuesday, reaching $235.13. 280,064 shares of the company were exchanged, compared to its average volume of 885,283. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $263.73. The stock has a fifty day simple moving average of $192.03 and a two-hundred day simple moving average of $171.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.